By: Anjali Thykattil, PharmD Candidate c/o 2025 and Isabelle Lim, PharmD Candidate c/o 2024 Effective June 23rd, 2023, the United States Food and Drug Administration (FDA) approved Pfizer’s LITFULO™ (ritlecitinib) for the treatment of severe alopecia areata in adults and adolescents above the age of 12 years. While ritlecitinib is the second FDA approved treatment…

By: Katelyn Hoosein, PharmD Candidate c/o 2025 and My Tram (Sophie) Le, PharmD Candidate c/o 2028 In recent years, there has been an increase in the prevalence of obesity in the United States. According to the National Heart, Lung, and Blood Institute (NHLBI), nearly 3 in 4 adults aged 20 years or older in the United…

By: Paulina Maczko, PharmD Candidate 2027, Sarah El-Rowmeim, PharmD Candidate 2027, and Laura Pham, PharmD Candidate 2025 Valoctocogene roxaparvovec-rvox, sold under the brand name “Roctavian” by BioMarin Pharmaceuticals, was approved by the Food and Drug Administration (FDA) on June 29, 2023. It is a single-dose adeno-associated virus vector-based gene therapy infusion indicated for the treatment…

By: Sameen Siddiqui, PharmD Candidate c/o 2025, Madelyn Lombardo, PharmD Candidate c/o 2027, and Gabriella Lamantea, PharmD Candidate c/o 2027 Breast cancer, besides skin cancer, is the most common cancer detected in women and one of the most common cancers linked to female mortality.1 Due to the silent rapidity of the disease, breast cancer can…